PremiumCompany AnnouncementsCervoMed Inc. Reports Q1 2025 Financial Results CervoMed Announces $50M Sales Agreement with Leerink CervoMed reports Q1 EPS (56c), consensus (62c) PremiumCompany AnnouncementsCervoMed Reports Positive Phase 2b Trial Results Is CRVO a Buy, Before Earnings? CervoMed to present results on Phase 2b RewinD-LB study PremiumThe FlyCervoMed price target raised to $21 from $12 at Canaccord Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float CervoMed reports FY24 EPS ($2.02), consensus ($1.85) 
